Literature DB >> 23204231

Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4.

Ravshan Burikhanov1, Tripti Shrestha-Bhattarai, Shirley Qiu, Nidhi Shukla, Nikhil Hebbar, Subodh M Lele, Craig Horbinski, Vivek M Rangnekar.   

Abstract

Tumor suppressor PAR-4 acts in part by modulating sensitivity to apoptosis, but the basis for its activity is not fully understood. In this study, we describe a novel mechanism of antiapoptosis by NF-κB, revealing that it can block PAR-4-mediated apoptosis by downregulating trafficking of the PAR-4 receptor GRP78 from the endoplasmic reticulum to the cell surface. Mechanistic investigations revealed that NF-κB mediated this antiapoptotic mechanism by upregulating expression of UACA, a proinflammatory protein in certain disease settings. In clinical specimens of cancer, a strong correlation existed between NF-κB activity and UACA expression, relative to normal tissues. UACA bound to intracellular PAR-4 in diverse cancer cells, where it prevented translocation of GRP78 from the endoplasmic reticulum to the cell surface. This pathway of antiapoptosis could be inhibited by suppressing levels of NF-κB or UACA expression, which enhanced endoplasmic reticulum stress and restored GRP78 trafficking to the cell surface, thereby sensitizing cancer cells to apoptosis by extracellular PAR-4 or GRP78 agonistic antibody. In summary, our results identify a novel intracellular pathway of apoptosis mediated by NF-κB through UACA elevation, which by attenuating endoplasmic reticulum stress and GRP78 translocation to the cell surface can blunt the sensitivity of cancer cells to apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23204231      PMCID: PMC3549021          DOI: 10.1158/0008-5472.CAN-12-3212

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Inflammatory disease and cancer with a decrease in Kupffer cell numbers in Nucling-knockout mice.

Authors:  Takashi Sakai; Li Liu; Xichuan Teng; Naozumi Ishimaru; Rika Mukai-Sakai; Nam Hoang Tran; Sun Mi Kim; Nobuya Sano; Yoshio Hayashi; Ryuji Kaji; Kiyoshi Fukui
Journal:  Int J Cancer       Date:  2010-03-01       Impact factor: 7.396

2.  The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis.

Authors:  Ravshan Burikhanov; Yanming Zhao; Anindya Goswami; Shirley Qiu; Steven R Schwarze; Vivek M Rangnekar
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

3.  Systemic Par-4 inhibits non-autochthonous tumor growth.

Authors:  Yanming Zhao; Ravshan Burikhanov; Jason Brandon; Shirley Qiu; Brent J Shelton; Brett Spear; Subbarao Bondada; Scott Bryson; Vivek M Rangnekar
Journal:  Cancer Biol Ther       Date:  2011-07-15       Impact factor: 4.742

4.  Phosphorylation of Par-4 by protein kinase A is critical for apoptosis.

Authors:  Sushma Gurumurthy; Anindya Goswami; Krishna Murthi Vasudevan; Vivek M Rangnekar
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

Review 5.  Inhibition of NF-κB signaling as a strategy in disease therapy.

Authors:  Thomas D Gilmore; Michael R Garbati
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 6.  GRP78 signaling hub a receptor for targeted tumor therapy.

Authors:  Masanori Sato; Virginia J Yao; Wadih Arap; Renata Pasqualini
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

Review 7.  Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting.

Authors:  Min Ni; Yi Zhang; Amy S Lee
Journal:  Biochem J       Date:  2011-03-01       Impact factor: 3.857

8.  IGFBP-3 binds GRP78, stimulates autophagy and promotes the survival of breast cancer cells exposed to adverse microenvironments.

Authors:  S Grkovic; V C O'Reilly; S Han; M Hong; R C Baxter; S M Firth
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

9.  Identification of a novel autoantigen UACA in patients with panuveitis.

Authors:  K Yamada; S Senju; T Nakatsura; Y Murata; M Ishihara; S Nakamura; S Ohno; A Negi; Y Nishimura
Journal:  Biochem Biophys Res Commun       Date:  2001-02-02       Impact factor: 3.575

Review 10.  NF-kappaB and IKK as therapeutic targets in cancer.

Authors:  H J Kim; N Hawke; A S Baldwin
Journal:  Cell Death Differ       Date:  2006-05       Impact factor: 15.828

View more
  28 in total

1.  4th international conference on tumor progression and therapeutic resistance: meeting report.

Authors:  Varun V Prabhu; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  A Naturally Generated Decoy of the Prostate Apoptosis Response-4 Protein Overcomes Therapy Resistance in Tumors.

Authors:  Nikhil Hebbar; Ravshan Burikhanov; Nidhi Shukla; Shirley Qiu; Yanming Zhao; Kojo S J Elenitoba-Johnson; Vivek M Rangnekar
Journal:  Cancer Res       Date:  2017-06-16       Impact factor: 12.701

3.  Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4.

Authors:  Ravshan Burikhanov; Tripti Shrestha-Bhattarai; Nikhil Hebbar; Shirley Qiu; Yanming Zhao; Gerard P Zambetti; Vivek M Rangnekar
Journal:  Cell Rep       Date:  2014-01-09       Impact factor: 9.423

4.  Anti-cancer activity of withaferin A in B-cell lymphoma.

Authors:  M K McKenna; B W Gachuki; S S Alhakeem; K N Oben; V M Rangnekar; R C Gupta; S Bondada
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

5.  ST08 Altered NF-κB Pathway in Breast Cancer Cells In Vitro as Revealed by miRNA-mRNA Analysis and Enhanced the Effect of Cisplatin on Tumour Reduction in EAC Mouse Model.

Authors:  Snehal Nirgude; Sagar Desai; Raghunandan Mahadeva; Febina Ravindran; Bibha Choudhary
Journal:  Front Oncol       Date:  2022-05-09       Impact factor: 5.738

6.  Prostate Apoptosis Response-4 (Par-4): A Novel Target in Pyronaridine-Induced Apoptosis in Glioblastoma (GBM) Cells.

Authors:  Jeevan Ghosalkar; Vinay Sonawane; Tejal Pisal; Swati Achrekar; Radha Pujari; Ashish Chugh; Padma Shastry; Kalpana Joshi
Journal:  Cancers (Basel)       Date:  2022-06-29       Impact factor: 6.575

7.  Development of 6H-Chromeno[3,4-c]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues.

Authors:  Mykhaylo S Frasinyuk; Svitlana P Bondarenko; Vitaliy M Sviripa; Ravshan Burikhanov; Vivek M Rangnekar; Chunming Liu; David S Watt
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

8.  Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin.

Authors:  Vitaliy M Sviripa; Ravshan Burikhanov; Josiah M Obiero; Yaxia Yuan; Justin R Nickell; Linda P Dwoskin; Chang-Guo Zhan; Chunming Liu; Oleg V Tsodikov; Vivek M Rangnekar; David S Watt
Journal:  Org Biomol Chem       Date:  2016-01-07       Impact factor: 3.876

9.  Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo.

Authors:  Ilona Rousalova; Sulagna Banerjee; Veena Sangwan; Kristen Evenson; Joel A McCauley; Robert Kratzke; Selwyn M Vickers; Ashok Saluja; Jonathan D'Cunha
Journal:  PLoS One       Date:  2013-10-15       Impact factor: 3.240

10.  Expression and regulation of prostate apoptosis response-4 (Par-4) in human glioma stem cells in drug-induced apoptosis.

Authors:  Jayashree C Jagtap; Parveen Dawood; Reecha D Shah; Goparaju Chandrika; Kumar Natesh; Anjali Shiras; Amba S Hegde; Deepak Ranade; Padma Shastry
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.